Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Investigating the Relationship Between GERD and Anxiety/Depression.

2.

In cancer survivors, loneliness is associated with a higher risk of death.

3.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

4.

MRI can save rectal cancer patients from surgery, study suggests

5.

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot